<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887728</url>
  </required_header>
  <id_info>
    <org_study_id>1901-ABU-002-BL</org_study_id>
    <nct_id>NCT03887728</nct_id>
  </id_info>
  <brief_title>Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles</brief_title>
  <official_title>Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles for IVF/ICSI, in Hormonal Replacement Cycles and Natural Cycles for Frozen Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ART Fertility Clinics LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ART Fertility Clinics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the blood flow in the aa. uterinae in women, undergoing firstly&#xD;
      ovarian stimulation for In-Vitro Fertilization (IVF) / Intracytoplasmic sperm injection&#xD;
      (ICSI), in Hormonal Replacement cycles (HRT) and Natural cycles (NC) for Frozen Embryo&#xD;
      Transfer (FET)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the influence of ovarian stimulation on the blood flow in the arteriae uterinae&#xD;
      as well as whether there is an influence of the type of endometrial preparation for FET with&#xD;
      either hormonal replacement therapy or natural cycle on the blood flow of the arteria uterina&#xD;
      left / right&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Actual">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">September 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the blood flow, calculated as Pulsatility Index (PI) and Resistance Index (RI), between the HRT- and the NC-FET cycles</measure>
    <time_frame>1 day</time_frame>
    <description>On the day of progesterone administration / progesterone rise. Quantitative continuous variable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous quantitative variable measured as the differences between average PI value</measure>
    <time_frame>1 day</time_frame>
    <description>On the day of cycle start and the day of ovulation induction. Continuous quantitative variable measured in millimeters (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous quantitative variable measured as the differences between average RI value</measure>
    <time_frame>2 days</time_frame>
    <description>On the day of cycle start and the day of ovulation induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of the lining</measure>
    <time_frame>1 day</time_frame>
    <description>Continuous quantitative variable measured in millimeters (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of estradiol exposure</measure>
    <time_frame>1 day</time_frame>
    <description>Before the embryo transfer</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">124</enrollment>
  <condition>Endometrial Receptivity</condition>
  <arm_group>
    <arm_group_label>Artificial (HRT) Cycles</arm_group_label>
    <description>Commence estradiol tablets (E2) 4mg from day 2 or 3 of period for 3 days&#xD;
Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.&#xD;
Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.&#xD;
Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.&#xD;
Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 10 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.&#xD;
Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily). Embryo transfer is scheduled 5 days following the initial initiation of progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spontaneous natural cycles</arm_group_label>
    <description>Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.&#xD;
Measurements of serum LH, estradiol and progesterone levels to determine ovulation.&#xD;
The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).&#xD;
Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5nmol /L confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary / secondary infertility, who undergo an ovarian stimulation treatment&#xD;
        for IVF/ICSI and subsequently are planned for FET with vitrified embryos, either as HRT-FET&#xD;
        or as NC-FET&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who undergo ovarian stimulation in a Gonadotropin-Releasing-Hormone&#xD;
             (GnRH)-antagonist protocol for IVF / ICSI&#xD;
&#xD;
          -  Patients who have vitrified embryo(s)&#xD;
&#xD;
          -  Preparation for FET either in HRT or NC cycle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor responder according to Bologna criteria (Ferraretti et al.) as follows:&#xD;
&#xD;
          -  At least two of the following three features must be present:&#xD;
&#xD;
          -  (i) Advanced maternal age (≥40 years) or any other risk factor for poor ovarian&#xD;
             reserve (POR);&#xD;
&#xD;
          -  (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol);&#xD;
&#xD;
          -  (iii) An abnormal ovarian reserve test (i.e. antral follicle count (AFC) 5-7 follicles&#xD;
             or anti-mullerian hormone (AMH) 0.5 -1.1 ng/ml).&#xD;
&#xD;
          -  Uterine surgery for removal of fibroids (hysteroscopic, laparoscopic) or removal of&#xD;
             uterine septum&#xD;
&#xD;
          -  Endometriosis&#xD;
&#xD;
          -  Asherman-Syndrome&#xD;
&#xD;
          -  Previous cytotoxic treatment&#xD;
&#xD;
          -  Previous radiation of the uterus / adnexal region&#xD;
&#xD;
          -  Known hypertension&#xD;
&#xD;
          -  Intake of Aspirin or similar medication which might influence the blood flow&#xD;
&#xD;
          -  Status after tubal ligation&#xD;
&#xD;
          -  Status after surgery in the adnexal region on 1 side&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Lawrenz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI RMA Abu Dhabi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI Middle East Fertility Clinic</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>60202</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>http://www.medicalcity-iq.net/medlib/Clinical%20Gynecologic%20Endocrinology%20and%20Infertility.pdf</url>
    <description>Clinical Gynecologic Endocrinology and Infertility Part 1. Reproductive Physiology. Chapter 6: Regulation of the Menstrual Cycle. Ovulation : 212-216p.</description>
  </link>
  <reference>
    <citation>Abdalla HI, Brooks AA, Johnson MR, Kirkland A, Thomas A, Studd JW. Endometrial thickness: a predictor of implantation in ovum recipients? Hum Reprod. 1994 Feb;9(2):363-5.</citation>
    <PMID>8027298</PMID>
  </reference>
  <reference>
    <citation>Noyes N, Liu HC, Sultan K, Schattman G, Rosenwaks Z. Endometrial thickness appears to be a significant factor in embryo implantation in in-vitro fertilization. Hum Reprod. 1995 Apr;10(4):919-22.</citation>
    <PMID>7650143</PMID>
  </reference>
  <reference>
    <citation>Bakos O, Lundkvist O, Bergh T. Transvaginal sonographic evaluation of endometrial growth and texture in spontaneous ovulatory cycles--a descriptive study. Hum Reprod. 1993 Jun;8(6):799-806.</citation>
    <PMID>8345066</PMID>
  </reference>
  <reference>
    <citation>Tekay A, Martikainen H, Jouppila P. Comparison of uterine blood flow characteristics between spontaneous and stimulated cycles before embryo transfer. Hum Reprod. 1996 Feb;11(2):364-8.</citation>
    <PMID>8671225</PMID>
  </reference>
  <reference>
    <citation>Romero R. Giants in Obstetrics and Gynecology Series: A profile of Leon Speroff, MD. Am J Obstet Gynecol. 2017 Sep;217(3):263.e1-263.e8. doi: 10.1016/j.ajog.2017.05.056. Epub 2017 Jul 12.</citation>
    <PMID>28710912</PMID>
  </reference>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <results_reference>
    <citation>Irani M, Robles A, Gunnala V, Reichman D, Rosenwaks Z. Optimal parameters for determining the LH surge in natural cycle frozen-thawed embryo transfers. J Ovarian Res. 2017 Oct 16;10(1):70. doi: 10.1186/s13048-017-0367-7.</citation>
    <PMID>29037231</PMID>
  </results_reference>
  <results_reference>
    <citation>Fatemi HM, Kyrou D, Bourgain C, Van den Abbeel E, Griesinger G, Devroey P. Cryopreserved-thawed human embryo transfer: spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil Steril. 2010 Nov;94(6):2054-8. doi: 10.1016/j.fertnstert.2009.11.036. Epub 2010 Jan 25.</citation>
    <PMID>20097333</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ART Fertility Clinics LLC</investigator_affiliation>
    <investigator_full_name>Barbara Lawrenz</investigator_full_name>
    <investigator_title>Scientific Director</investigator_title>
  </responsible_party>
  <keyword>progesterone</keyword>
  <keyword>endometrium</keyword>
  <keyword>blood flow</keyword>
  <keyword>estradiol</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03887728/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

